CRP and depressive disorder: The recent study by Raison et al (2013) on the efficacy of infliximab on treatment resistant depression finds that only ~30–40% of depressed patients (based on the criteria) present with raised inflammatory markers (CRP) at baseline, and it is likely that the distribution of high-inflammation genetic variants will be different in these patients compared with those with no peripheral inflammation.